Profile: Acura Pharmaceuticals Inc (ACUR.O)
13 Jan 2017
Acura Pharmaceuticals, Inc., incorporated on April 10, 1935, is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three proprietary platform technologies, which can be used to develop multiple products.
The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede Technology products include Nexafed and Nexafed Sinus Pressure + Pain product. The Company has multiple pseudoephedrine products in development utilizing its Impede Technology. The Company's third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.
The Company develops hydrocodone bitartrate with acetaminophen product utilizing its Limitx technology. The Company develops products by utilizing Limitx technology, which include immediate-release hydromorphone HCI (LTX-04) and immediate-release hydrocodone bitartrate with acetaminophen (LTX-03). The Company's Phase I exploratory pharmacokinetic study, AP LTX 400 on LTX-04 is in process. The Company's formulation development of LTX-03 is in process.
The Company's Aversion Technology and related opioid products, like Oxaydo, are covered by claims in five issued the United States patents. The Company's Aversion Technology products are intended to provide the same therapeutic benefits of the active drug ingredient as marketed products containing the same active pharmaceutical ingredient. The Company's Oxaydo (oxycodone HCI tablets) is a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.
The Company's Impede 1.0 Technology, which is a mixture of inactive ingredients, prevents the extraction of peculiar support equipment (PSE) from tablets using known extraction methods and disrupts the direct conversion of PSE from tablets into methamphetamine. The Company's Impede 2.0 Technology is to improve the meth-resistance of its technology. The Company's Nexafed product line consists of immediate release tablets, which utilizes its Impede 1.0 Technology. The Company's Nexafed is approximately 30 milligram pseudoephedrine tablet and Nexafed Sinus Pressure + Pain is approximately 30/325 milligram pseudoephedrine and acetaminophen tablet. The Company's IR opioid products include Hydrocodone, Oxycodone, Tramadol, Codeine and three others.
Acura Pharmaceuticals Inc
616 N North Ct Ste 120
PALATINE IL 60067-8121